Close

PhRMA welcomes Trump's inauguration as 47th United States President; organization commits to working with administration on healthcare innovation and cost reduction

Jan 20, 2025 Press Release 2 min read

Exclusive Industry Insights

By submitting, you agree to our Privacy Policy

Share this article:

January 20, 2025 (press release) –

WASHINGTON, D.C. (January 20, 2025) – Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the following statement congratulating President Donald Trump on his inauguration as the 47th President of the United States:

“We look forward to working with the Trump administration and Congress to tackle our country’s biggest health care challenges. By focusing on prevention and mitigation of chronic diseases, we can improve patient outcomes, lower costs, and create a healthier future for all Americans.

“The pharmaceutical industry is the crown jewel of the American economy, giving American patients more treatment options than anywhere else in the world while supporting millions of high-paying, high-tech jobs around the country. Through innovation we’ve achieved significant breakthroughs, improved cancer survival rates, cured hepatitis C, and eradicated devastating diseases like polio and smallpox. New medicines are transforming our ability to prevent, treat, and cure deadly diseases more effectively, improving patient lives and reducing reliance on the most expensive parts of the health care system.

“To sustain this progress, we must preserve and strengthen America’s world-leading innovation ecosystem, which balances groundbreaking advancements with affordability, by encouraging the development of new treatments that eventually lead to lower-cost generics and biosimilar medicines. The Inflation Reduction Act, which is undermining U.S. leadership in medical innovation, must be addressed to ensure continued investment in life-changing treatments.

“Additionally, we must hold other players in the health care system accountable for driving up costs. PBM reform remains a top priority, as does addressing the misuse of the 340B program. Our industry remains committed to ensuring that patients, taxpayers, and employers see lower costs from the rebates and discounts that PBMs, insurers, and hospitals get off the price of medicine.

“We look forward to working together to build a stronger health care system – one that delivers better outcomes, greater affordability, and sustained innovation for the benefit of all Americans.”

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

Stay Ahead of Changes

Don't Wait. Stay Informed.

The world and your industry are changing too fast. You need to know what's happening, and our Legislation Monitor can help. It's a critical resource for anyone who wants to stay ahead of regulatory and legal challenges. Then, discover the other ways that Industry Intelligence Inc. can help your business.

Cookie Preferences

This website uses cookies to enhance your browsing experience, analyze site performance, and deliver personalized content. We use a minimal cookie to remember your preferences. For detailed information about our cookie usage, please review our Privacy Policy.